Virogin Biotech is at the forefront of cancer treatment innovation, focusing on two primary technology platforms: oncolytic virotherapy using a modified herpes simplex virus type 1 (HSV-1) and mRNA-based therapeutics, including self-amplifying RNA (saRNA). The oncolytic virus platform is designed to selectively target and destroy cancer cells while stimulating a robust immune response. Virogin's lead candidate, VG161, has shown promising results in clinical trials, particularly for patients with advanced hepatocellular carcinoma (HCC) and sarcoma, demonstrating significant improvements in overall survival and progression-free survival. This platform allows for the delivery of therapeutic payloads, such as interleukins, enhancing the anti-tumor immune response.

Complementing the oncolytic virus technology, Virogin's mRNA platform focuses on developing cancer vaccines that can elicit durable immune responses against solid tumors. The company employs a heterologous prime-boost strategy, which combines the strengths of both platforms to enhance systemic anti-tumor immunity. This approach aims to overcome the immunosuppressive tumor microenvironment by exposing more tumor antigens through the lysis of tumor cells by the oncolytic virus, thereby improving the efficacy of mRNA vaccines. Virogin's commitment to advancing these innovative therapies positions it as a key player in the evolving landscape of cancer immunotherapy.

Canada

Virogin Biotech is a biotechnology company that specializes in oncolytic virus drug development to create impactful drugs for patients with the highest medical need.

Virogin Biotech

Company Details